— Sunesis Pharmaceuticals (NASDAQ: SNSS) reported loss of $0.05 per share in the fourth quarter of 2019, vs $0.07 per share loss expected.
— Net revenue rose to $2.1 billion, vs. $310,000 expected. The growth in topline was driven by revenue recognized from the upfront payments received under the license agreements with DOT-1 and Denovo.
— Cash and cash equivalents rose to $34.6 million, from $13.7 million a year ago. The growth was primarily due to net proceeds from the issuance of common and preferred stock, and proceeds from the SVB loan.
— SNSS shares fell over 2% immediately following the announcement.
The positive effects of widespread digitalization and e-commerce growth on China’s financial services industry became more pronounced during the pandemic as the movement restrictions drove more retail customers to online
Shares of Activision Blizzard Inc. (NASDAQ: ATVI) were up 1.6% on Thursday. The stock has dropped 14% since the start of the year. The company has been in the news
The emergence of technology-driven financial services is making people think beyond conventional banks when it comes to availing loans and transferring funds. In a move aimed at taking its business